CAS 1174122-54-3

Formula: C19H18F6N4O3

InChI: InChI=1S/C19H18F6N4O3/c1-32-17(31)16-14-8-28(2-3-29(14)18(27-16)19(23,24)25)15(30)6-10(26)4-9-5-12(21)13(22)7-11(9)20/h5,7,10H,2-4,6,8,26H2,1H3/t10-/m1/s1

InChI key: WIIAMRXFUJLYEF-SNVBAGLBSA-N

SMILES: COC(=O)C1=C2CN(CCN2C(=N1)C(F)(F)F)C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N

Methyl 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)imidazo[1,5-a]pyrazine-1-carboxylate

CAS: 1174122-54-3

Methyl 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)imidazo[1,5-a]pyrazine-1-carboxylate

Formula: C₁₉H₁₈F₆N₄O₃

Purezza: 98.30%

Peso molecolare: 464.36

Ref: 54-PC1032813

Retagliptin

CAS: 1174122-54-3

Retagliptin is a DPP-4 inhibitor potentially used to treat Type 2 diabetes.

Formula: C₁₉H₁₈F₆N₄O₃

Colore e forma: Solid

Peso molecolare: 464.36

Ref: TM-T28520

Retagliptin

CAS: 1174122-54-3

Formula: C₁₉H₁₈F₆N₄O₃

Peso molecolare: 464.37

Ref: ST-EA-CP-R117000

Retagliptin

CAS: 1174122-54-3

Retagliptin is a dpp-iv inhibitor, which lowers blood glucose levels by stimulating the release of insulin from the pancreas. It is used to diagnose patients with ventricular dysfunction and cardiac arrhythmia. Retagliptin has been shown to be effective in diabetics with heart disease and healthy Chinese patients, although it is not approved for use in India. Retagliptin can be taken orally or intravenously. It does not have any significant side effects and can be used for long periods of time without any need for dosage adjustments. Retagliptin also has a small-molecule drug structure that makes it suitable for use as a diagnostic agent in analytical methods such as mass spectrometry and nuclear magnetic resonance spectroscopy.

Purezza: Min. 95%

Ref: 3D-FR57620